HSCS (HeartSciences) LT-Debt-to-Total-Asset: 0.08 (As of Jan. 2026)

What is HeartSciences LT-Debt-to-Total-Asset?

HeartSciences HSCS -1.18% 42 LT-Debt-to-Total-Asset is 0.08 as of Jan. 2026. GuruFocus rates HSCS with a GF Score™ of 42/100 and a GF Value™ of $2.61 (Modestly Overvalued). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. HeartSciences's long-term debt to total assests ratio for the quarter that ended in Jan. 2026 was 0.08.

HeartSciences's long-term debt to total assets ratio increased from Jan. 2025 (0.06) to Jan. 2026 (0.08). It may suggest that HeartSciences is progressively becoming more dependent on debt to grow their business.

HeartSciences (NAS:HSCS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

HeartSciences LT-Debt-to-Total-Asset Related Terms

HeartSciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for HeartSciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeartSciences LT-Debt-to-Total-Asset Chart

HeartSciences Annual Data

Trend

Apr20

Apr21

Apr22

Apr23

Apr24

Apr25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

1.35

2.13

0.32

0.05

0.08

HeartSciences Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.08	0.04	0.04	0.08

42GF Score

HeartSciences Inc HSCS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

HeartSciences LT-Debt-to-Total-Asset Calculation

HeartSciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2025 is calculated as

LT Debt to Total Assets (A: Apr. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Apr. 2025 )	/	Total Assets (A: Apr. 2025 )
	=	0.315	/	4.223
	=	0.07

HeartSciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2026 is calculated as

LT Debt to Total Assets (Q: Jan. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2026 )	/	Total Assets (Q: Jan. 2026 )
	=	0.633	/	7.555
	=

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.08 mean?

HeartSciences (HSCS) has a LT-Debt-to-Total-Asset of 0.08 as of Jan. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on HeartSciences and its competitors.

Is HeartSciences' LT-Debt-to-Total-Asset too high?

HeartSciences' current LT-Debt-to-Total-Asset is 0.08. Overall, HeartSciences has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does HeartSciences' LT-Debt-to-Total-Asset compare to CSDX and CODX?

HeartSciences' LT-Debt-to-Total-Asset of 0.08 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on HeartSciences and its competitors. HeartSciences's current LT-Debt-to-Total-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is HeartSciences stock overvalued right now?

Based on GuruFocus' analysis, HeartSciences (HSCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.61, compared to a current price of $2.90 — trading 11.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.08. HeartSciences' overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For HeartSciences (HSCS), the current LT-Debt-to-Total-Asset is 0.08 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HeartSciences (HSCS) Overvalued in 2026?

Based on GuruFocus' analysis, HeartSciences stock appears to be overvalued. The current stock price of $2.90 is trading 11.1% above its estimated GF Value™ of $2.61. GuruFocus considers HeartSciences to be Modestly Overvalued.

Key valuation signals for HSCS:

LT-Debt-to-Total-Asset: 0.08
GF Value™: $2.61 vs. price of $2.90 (11.1% above fair value)
GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the HSCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HeartSciences Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies CSDX CODX ALRTF NXL STME NVNO AIDX TRIB SINT VVOS ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092

Website https://www.heartsciences.com

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

42GF Score

Get the complete analysis for HSCS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.90

Price

$2.61

GF Value

View HSCS Analysis

See LT-Debt-to-Total-Asset data for all stocks →